Sign In
Buy EXEL
$51.60
+3.06 (+6.30%)
At Close: Jun 03, 2026
3 Top Biotech Stocks to Buy Right Now
06:09am, Saturday, 19'th Dec 2020
Each of them should enjoy strong sales growth in 2021 and beyond.
ALAMEDA, Calif., SOUTH SAN FRANCISCO, Calif. & VANCOUVER, British Columbia--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL), Iconic Therapeutics, Inc. (Iconic) and Zymeworks Inc. (NYSE:ZYME) today anno
Exelixis, Inc. (EXEL) CEO Mike Morrissey Presents at Evercore ISI 3rd Annual HealthCONx (Transcript)
05:48pm, Tuesday, 01'st Dec 2020
Exelixis, Inc. (EXEL) CEO Mike Morrissey Presents at Evercore ISI 3rd Annual HealthCONx (Transcript)
ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (NASDAQ: EXEL) today announced that Takeda Pharmaceutical Company Limited (Takeda), its partner responsible for the clinical development and commercial
Got $50? 4 Smart Stocks to Buy Into Right Now
05:51am, Friday, 27'th Nov 2020
You don't need to start with a fortune to build wealth on Wall Street.
Exelixis to Webcast Fireside Chats as Part of Virtual Investor Conferences in December
05:30pm, Monday, 23'rd Nov 2020
ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced that members of the company's management team will participate in fireside chats at the following virtual investor confe
Exelixis, Inc. (EXEL) CEO Michael Morrissey Presents at Stifel 2020 Virtual Healthcare Conference (Transcript)
04:50pm, Wednesday, 18'th Nov 2020
Exelixis, Inc. (EXEL) CEO Michael Morrissey Presents at Stifel 2020 Virtual Healthcare Conference (Transcript)
Exelixis' (EXEL) CEO Mike Morrissey on Q3 2020 Results - Earnings Call Transcript
01:19am, Friday, 06'th Nov 2020
Exelixis' (EXEL) CEO Mike Morrissey on Q3 2020 Results - Earnings Call Transcript
Exelixis (EXEL) Reports Q3 Loss, Tops Revenue Estimates
08:30pm, Thursday, 05'th Nov 2020
Exelixis (EXEL) delivered earnings and revenue surprises of -100.00% and 7.05%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
Were These Hedge Funds Wrong About Exelixis, Inc. (EXEL)?
12:46pm, Tuesday, 03'rd Nov 2020
Is Exelixis, Inc. (NASDAQ:EXEL) a good place to invest some of your money right now? We can gain invaluable insight to help us answer that question by studying the investment trends of top investors,
Is Exelixis Stock a Buy?
06:32am, Tuesday, 03'rd Nov 2020
The pharmaceutical company is moving beyond its longtime reliance on a single cancer drug, but what will those changes mean for shareholders?
4 Safe Stocks to Buy and Hold for the Next 4 Years
05:51am, Tuesday, 03'rd Nov 2020
The election won't impact the ability of these great companies to deliver for their shareholders.
Better Buy: Illumina vs. Exelixis
06:57am, Wednesday, 28'th Oct 2020
These two stocks have very different methods of generating returns.
Exelixis' (EXEL) Applications for Cabometyx-Opdivo Combo Accepted (Revised)
04:38am, Wednesday, 28'th Oct 2020
Exelixis' (EXEL) applications for Cabometyx in combination with Opdivo for the treatment of RCC has been accepted by the FDA.
ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (NASDAQ: EXEL) today announced that Takeda Pharmaceutical Company Limited (Takeda), its partner responsible for the clinical development and commercial
